A phase 2 trial of SIR2501 in advanced solid tumours, run by Sironax USA, Inc., now recruiting.
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel is a phase 2 interventional study registered as NCT07765446 by Sironax USA, Inc., with 18 participants planned, started 2026-08-21 and due to reach its primary completion in 2027-12-31. Interventions recorded: SIR2501.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.